ClinicalTrials.gg
WithdrawnNCT00888082PROOFUpdated Dec 10, 2010

Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy

A Phase 3 interventional study of Goserelin acetate in Breast Cancer and Ovarian Function, sponsored by AstraZeneca. Withdrawn at 3 sites in Turkey. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2010-12-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.

Planned enrollment
22nd of 41
102 · median 147
Phase 3
15 of 43
none open now
Registered
17th of 43
by date
Lead sponsor
5 of 43
AstraZeneca

Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 22nd largest by planned enrollment of the 41 interventional ones that give a count, is one of 15 in phase 3, and was the 17th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing goserelin in Breast Neoplasms, or all of them as a file.
02

Study summary

Primary objective of this study is to determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing adjuvant chemotherapy for primary invasive breast cancer by documenting persistence or resumption of regular menses via menstrual history, serum FSH and E2 measurements.

The secondary objectives of this study are as follows: To investigate the impact of treatment with chemotherapy with or without goserelin acetate (i.e. impact of the expectation of ovarian function preservation) on participants' quality of life (QOL) by FACT-ES scale, and to compare safety and tolerability of study drugs in two treatment groups by evaluation of adverse events.

03

Conditions studied

  • Breast Cancer
  • Ovarian Function

Browse trials for

Keywords

  • adjuvant chemotherapy
  • breast cancer
  • goserelin acetate
  • ovarian function
  • Chemotherapy
  • Primary invasive breast cancer
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive breast carcinoma
  • Candidates for chemotherapy for primary breast cancer
  • Premenopausal, verified before chemotherapy is begun as satisfying both cyclic vaginal bleeding and appropriate hormone levels

Exclusion criteria

Exclusion Criteria:

  • Previous systemic chemotherapy
  • Pregnancy
  • Stage IV breast cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • No intervention
    A

    Patients receiving only adjuvant chemotherapy

  • Experimental
    B

    Patient receiving goserelin acetate along with adjuvant chemotherapy

    Drug: Goserelin acetate

Interventions

  • 3.6 mg depot injectable preparation

    Also known as: Zoladex 3.6 mg Depot

06

What researchers measure

Primary outcomes

  1. The ovarian function will be considered as regained, if E2 measurements return to premenopausal levels (equal to or above 20 pg/ml), FSH measurements return to premenopausal levels (less than or equal to 40 IU/L)

    Time frame: Each 3 months

  2. The ovarian function will be considered as regained, if menstrual bleeding is observed in two consecutive menstrual cycles

    Time frame: Each 3 months

Secondary outcomes

  1. Quality of life (QOL) through-out the study measured by FACT-ES scale.

    Time frame: Each 3 months

07

Study locations

3 sites
  • Research Site
    Ankara, Turkey
  • Research Site
    Istanbul, Turkey
  • Research Site
    Kayseri, Turkey
08

References and documents

Publications

  • Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995 Feb;52(2):365-72. doi: 10.1095/biolreprod52.2.365. PubMed 7711205 ↗
  • Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res. 1985 Aug;45(8):3651-6. PubMed 3926307 ↗
  • Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May;14(5):1718-29. doi: 10.1200/JCO.1996.14.5.1718. PubMed 8622093 ↗
  • Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr. 2005;(34):40-3. doi: 10.1093/jncimonographs/lgi015. PubMed 15784821 ↗
  • Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer. 1990 Jun;61(6):861-5. doi: 10.1038/bjc.1990.192. PubMed 2142603 ↗
  • Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, Panduro J, Andersen KW. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol. 1987 Nov;5(11):1771-8. doi: 10.1200/JCO.1987.5.11.1771. PubMed 3316514 ↗
  • Cheer SM, Plosker GL, Simpson D, Wagstaff AJ. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs. 2005;65(18):2639-55. doi: 10.2165/00003495-200565180-00011. PubMed 16392882 ↗
  • Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, Clavarezza M, Testa D, Venturini M. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006 Jan;17(1):74-8. doi: 10.1093/annonc/mdj029. Epub 2005 Oct 27. PubMed 16254024 ↗
  • Del Mastro L, Venturini M, Sertoli MR et al. Phase III adjuvan trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO-MIG1 study. Breast Cancer Res Treat 2003; 82 (Suppl 1): S9 (Abstr).
  • Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997 Apr;43(2):183-90. doi: 10.1023/a:1005792830054. PubMed 9131274 ↗
  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 Sep 19;352(9132):930-42. PubMed 9752815 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00888082
Lead sponsor
AstraZeneca
First posted
Apr 24, 2009
Primary completion
Apr 2012 (estimated)
Completion
Apr 2012 (estimated)
Last update
Dec 10, 2010

Study contacts

Mustafa Özgüroğlu, Assoc.Prof.
study chair · Istanbul University Cerrahpasa Medical Faculty, Medical Oncology Clinic, Cerrahpasa 34098, Istanbul, Turkey
Yeşim Eralp, Assoc.Prof.
principal investigator · Istanbul University Istanbul Medical Faculty, Oncology Institute, Medical Oncology Department, Capa 34360 Istanbul, Turkey
Gül Başaran, Assoc.Prof.
principal investigator · Marmara University Medical Faculty, Medical Oncology Department, Istanbul, Turkey
Kadri Altundağ, Prof.
principal investigator · Hacettepe University Medical Faculty, Medical Oncology Department, Sihhiye 06100 Ankara, Turkey
Filiz Çay Şenler, Assoc.Prof.
principal investigator · Ankara University Medical Faculty, Medical Oncology Department, Sihhiye 06100 Ankara, Turkey
Metin Özkan
principal investigator · Erciyes University Medical Faculty, Medical Oncology Department, 38039 Kayseri, Turkey

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion